Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level.
BACKGROUND Lipid-lowering agents are known to reduce long-term mortality in patients with stable angina or multiple risk factors . However , the effects of lipid-lowering treatment on inflammatory process during and immediately after the acute phase of unstable angina remain unclear . In this study we assessed the effects of low-dose atorvastatin treatment , on inflammatory process in patients admitted for unstable angina with low cholesterol level . METHODS Forty-seven normocholesterolemic patients with unstable angina were r and omized into two groups , and received atorvastatin 10 mg/day ( n = 24 ) or no statin ( n = 23 ) for 6 weeks . Circulating levels of inteleukin 6 ( IL-6 ) , monocyte chemoattractant protein-1 ( MCP-1 ) , tumor necrosis factor alpha ( TNF-alpha ) and soluble vascular cell adhesion molecule ( sVCAM-1 ) were measured by their admission , and at the 1st and 6th week of the study . RESULTS Serum levels of MCP-1 and sVCAM-1 were significantly increased in the control group ( p < 0.05 ) while remained unaffected in the atorvastatin-treated group six weeks after admission . However , IL-6 and TNF-alpha levels were similarly decreased in both atorvastatin-treated and control groups . CONCLUSION Low-dose atorvastatin treatment modifies inflammatory process in patients with unstable angina and low cholesterol level , an effect seen at 6 weeks but not 1 week after admission
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .